Why is argenx SE (ARGX) stock up today?
argenx surged after Q2 earnings crushed estimates, with Vyvgart (its flagship autoimmune drug) posting 60% sales growth and EPS beating Wall Street by 17%.
What happened
argenx shares rose 8.56% to $924.60 on July 23, 2026 — climbing from a previous close of $851.72 and touching an intraday high of $927.08 — after the company reported second-quarter 2026 results that handily beat analyst expectations. EPS came in at $7.32, surpassing the consensus estimate of $6.24 by roughly 17%, and representing a near-doubling (95.72% increase) from the $3.74 earned in the same quarter a year earlier. Quarterly sales reached $1.542 billion, above the $1.442 billion estimate.
The central driver of the beat was Vyvgart, argenx's blockbuster treatment for autoimmune diseases, whose sales rose 60% year-over-year. That level of growth in a single product, combined with total operating income rising alongside profits, signaled to the market that Vyvgart's commercial momentum remains strong. With pipeline readouts also approaching, traders interpreted the results as confirmation that the company's core business and future prospects are on track.
The gains came despite a broadly weak market session: the S&P 500 fell 1.21% and the Nasdaq-100 (tracked by QQQ) dropped 1.90% on the same day. argenx's ability to surge roughly 8.5% against a broad market selloff underscores how sharply the earnings beat and Vyvgart's growth distinguished it from the general risk-off backdrop.
As of market close, argenx carries a market capitalization of approximately $57.50 billion. The stock is listed as an American Depositary Receipt (ADR) in the U.S., representing shares in a Belgian biopharmaceutical company. The earnings-driven move puts the share price near its intraday high of $927.08, with pipeline data readouts cited as the next major events to watch.
The catalysts, cited
argenx Q2 EPS of $7.32 beats the $6.24 estimate by 17%, marking a ~96% year-over-year increase; sales of $1.542B top the $1.442B estimate.
Benzinga
Vyvgart sales rise 60% year-over-year as pipeline readouts approach.
InvestorsHub
argenx Q2 profit and total operating income rise, per half-year financial results report.
MT Newswires
argenx reports half year 2026 financial results and provides second quarter business update.
GlobeNewswire
What to watch next
- Upcoming pipeline readouts for Vyvgart and other pipeline programs
People also ask
Why is argenx stock going up today?
argenx reported Q2 2026 earnings that beat Wall Street estimates on both profit and sales. EPS of $7.32 exceeded the $6.24 consensus by about 17%, and revenue of $1.542 billion topped the $1.442 billion estimate, driving the stock up roughly 8.56%.
Why did ARGX stock jump so much when the rest of the market is down?
The broader market sold off on July 23, with the S&P 500 falling 1.21% and the Nasdaq-100 dropping 1.90%. argenx bucked that trend because its quarterly earnings beat and Vyvgart's 60% sales growth gave investors company-specific reasons to buy, overriding the general market weakness.
What is Vyvgart and why does it matter for ARGX?
Vyvgart is argenx's lead drug for treating autoimmune diseases. Its sales rose 60% year-over-year in Q2 2026, making it the primary engine behind the company's revenue beat and profit growth this quarter.
What should I watch next for ARGX stock?
According to news published alongside the Q2 results, pipeline readouts are approaching, meaning clinical trial data from other argenx drug programs are expected in the near term. Those results could serve as the next significant catalyst for the stock.